By Lisa Kerner
Charlotte, N.C., July 5 - NanoMed Pharmaceuticals, Inc. said it closed its first round of venture financing, led by the SWMF Life Science Venture Fund.
Proceeds will be used to continue development of the company's nanoparticle-based drugs for patients undergoing chemotherapy for leukemia and breast cancer.
NanoMed's corporate headquarters will be located in Kalamazoo, Mich., while its labs initially will be located at the Advanced Science & Technology Commercialization Center on the campus of the University of Kentucky.
NanoMed develops nanoparticle-based therapeutic and diagnostic products to treat or detect disease, including cancer.
| Issuer: | NanoMed Pharmaceuticals, Inc.
|
| Issue: | Venture financing
|
| Amount: | Undisclosed
|
| Investor: | SWMF Life Science Venture Fund
|
| Announcement date: | July 5
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
